BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, informed its shareholders that BioInvent does not hold cash deposits or securities at Silicon Valley Bank, or any other foreign bank.
